share_log

Morgan Stanley Upgrades Axsome Therapeutics to Overweight, Raises Price Target to $115

Benzinga ·  Apr 29 05:27

Morgan Stanley analyst Vikram Purohit upgrades Axsome Therapeutics (NASDAQ:AXSM) from Equal-Weight to Overweight and raises the price target from $90 to $115.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment